Synchron, the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Andy Rasdal to its Board of Directors. Mr. Rasdal brings more than 30 years of experience of developing and commercializing novel medical devices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211125159/en/

Andy Rasdal, Board Member, Synchron (Photo: Business Wire)

As former CEO of DexCom, Inc. (NASDAQ:DXCM, Market Cap: $46 billion))) he led the company through FDA approval, a successful IPO, and commercialization of its continuous glucose monitor (CGM) product for diabetes. He currently serves as executive chairman of Epitel, a company that developed the first wearable, wireless EEG system to detect seizure conditions. As founding CEO of Obalon Therapeutics, Inc., he led the company through FDA PMA approval, an IPO, and commercialization of a novel product for obesity.

"Andy joining the Board is a windfall for Synchron. He brings decades of operational experience in delivering first-to-market products through the FDA premarketing approval pathway," said Tom Oxley, CEO & Founder, Synchron. "His career exposure to over 15 PMAs, in particular, leading DexCom through FDA approval and an eventual IPO, will be invaluable to Synchron."

"I'm excited to join the Synchron Board of Directors. I believe in the company's mission to become the first implantable brain computer interface to reach commercialization and help millions of people with paralysis reconnect with the world," Rasdal said. "My experience is relevant to Synchron, especially as they move towards pivotal study launch and eventual commercialization. Synchron has a broad technology platform with the potential to become the market-leading implantable neurotechnology company."

Before DexCom, Mr. Rasdal was President, Medtronic Vascular. Mr. Rasdal was the Vice President of Global Marketing at Arterial Vascular Engineering, Inc. (AVEI) which was purchased by Medtronic for $4.3 billion. Prior to AVE, Mr. Rasdal also held positions at EP Technologies (EPTI), which was acquired as a public company by Boston Scientific, and Advanced Cardiovascular Systems (ACS), which became the vascular division of Guidant and was ultimately acquired by Abbott.

Mr. Rasdal holds a Masters of Management from the Kellogg Graduate School of Management and a B.Sc. from San Jose State University.

About Synchron

Synchron is a neurotechnology company developing an endovascular brain-computer interface (BCI) designed to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices and restore autonomy for individuals with motor impairment. Synchron is headquartered in New York City. For more information, visit www.synchron.com. Follow us @synchroninc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231211125159/en/